Template:Second-generation BTKi table: Difference between revisions
From Embryology
mNo edit summary |
mNo edit summary |
||
| Line 4: | Line 4: | ||
! width=120px|BTK inhibitor | ! width=120px|BTK inhibitor | ||
! width=120px|BTK binding mechanism | ! width=120px|BTK binding mechanism | ||
! Selectivity for BTK | ! width=120px|Selectivity for BTK | ||
! width=200px|Relevant non-BTK targets | ! width=200px|Relevant non-BTK targets | ||
! width=120px|Phase of clinical development | ! width=120px|Phase of clinical development | ||
Revision as of 14:03, 30 April 2019
| BTK inhibitor | BTK binding mechanism | Selectivity for BTK | Relevant non-BTK targets | Phase of clinical development |
|---|---|---|---|---|
| Acalabrutinib | Covalent, irreversible | High | N/A | II/III |
| Zanubrutinib | Covalent, irreversible | Moderate | N/A | II/III |
| Tirabrutinib | Covalent, irreversible | High | N/A | I/II |
| Vecabrutinib | Non-covalent, reversible | Moderate | interleukin-2-inducible (ITK) | I/II |
| LOXO-305 | Non-covalent, reversible | High | N/A | I |
| ARQ-531 | Non-covalent, reversible | Low | Lck/Yes novel tyrosine kinase (LYN), mitogen-activated protein kinase kinase 1 (MEK1) | I |
| Table data [1] | ||||
